Filing Flows › Harvard Bioscience (HBIO) › Q1 2025
Harvard Bioscience (HBIO) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 12, 2025
Harvard Bioscience (HBIO) reported revenue of $21.8M for the first quarter 2025 (Q1 2025), -11% from a year earlier and -11% from the quarter before. Operating margin was -228.1%, net loss $50.3M (231.2% of revenue).
Harvard Bioscience, Q1 2025: revenue $21.8M (-11% year over year), operating margin -228.1%, net loss $50.3M, operating cash flow $3.0M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $21.8M | -11% | -11% |
| Operating profit | −$49.7M | -451627% | — |
| Net earnings | −$50.3M | -279767% | — |
| Operating cash flow | $3.0M | +73% | +113% |
| Free cash flow | $2.5M | +74% | +226% |
What changed
Revenue was $21.8M in Q1 2025, down 11% year over year and down 11% from the previous quarter. Instruments, Equipment, Software, and Accessories was the largest line at 91% of revenue. Instruments, Equipment, Software, and Accessories lost $2.9M year over year (down 13%), 106% of the total change.
Gross margin was 56.0%, down 4.3 points from a year earlier. Operating costs exceeded revenue by $49.7M, an operating margin of -228.1%. Operating expenses grew 263% against a revenue fall of 11%. The fastest-growing cost line was Other operating costs (+2048%). The quarter ended with a net loss of $50.3M, after a profit of $18K the previous quarter.
Operating cash flow was $3.0M (up 113% year over year). Non-cash charges added back $1.6M of depreciation and amortization and $600K of share-based compensation. Working capital and other items added $51.1M. Capital expenditures of $513K left free cash flow of $2.5M.
Questions
What was Harvard Bioscience's revenue in the first quarter 2025?
Harvard Bioscience (HBIO) reported revenue of $21.8M for the first quarter 2025 (Q1 2025), -11% from a year earlier and -11% from the quarter before.
Was Harvard Bioscience profitable in the first quarter 2025?
Operating loss was $49.7M (-228.1% of revenue) and net loss $50.3M.
Source: Harvard Bioscience 10-Q on SEC EDGAR.